从脂肪组织角度探讨2型糖尿病的发病机制及治疗。

IF 3 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Zezheng Kang, Zishan Jin, Lei Wu, Aru Sun, Lishuo Dong, Jiarui Li, Qingwei Li, Xiaolin Tong
{"title":"从脂肪组织角度探讨2型糖尿病的发病机制及治疗。","authors":"Zezheng Kang, Zishan Jin, Lei Wu, Aru Sun, Lishuo Dong, Jiarui Li, Qingwei Li, Xiaolin Tong","doi":"10.2147/DMSO.S524000","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) has a high prevalence worldwide; its cardiac, renal, and visual complications greatly affect patients' quality of life. This, together with the large patient base, makes clinical health management of T2DM a problem. Existing studies have shown that obesity and the onset of T2DM are highly correlated, which can start from the earliest lipid metabolism problems and ultimately develop into T2DM. Moreover, adipose tissue can also seriously affect patient treatment by affecting insulin secretion, promoting pancreatic β-cell proliferation, and increasing insulin resistance. Our study describes the association between obesity and T2DM, summarizes the role played by the adipose tissue in T2DM, and focuses on fatty acid esters of hydroxy fatty acids (FAHFA), whose role in improving insulin secretion and increasing insulin sensitivity shows greater potential in T2DM. In addition, we summarize the existing more mature clinical treatment strategies, such as life interventions, drugs, and surgery, which can help control blood glucose levels and reduce adipose-related insulin resistance by reducing the adipose tissue. Among these treatments, Chinese medicine is another factor worth exploring. However, due to the influence of geography, culture, and other factors, this method has only achieved some success in China and part of the East Asia region and has been applied clinically. Although there is no evidence of clinical benefit for obesity or adipose tissue, its clinical benefit for T2DM has been demonstrated; therefore, there is still a need to develop it, as well as considerable potential for development.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"2343-2360"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273715/pdf/","citationCount":"0","resultStr":"{\"title\":\"Investigating the Pathogenesis and Treatment of Type 2 Diabetes from the Perspective of Adipose Tissue.\",\"authors\":\"Zezheng Kang, Zishan Jin, Lei Wu, Aru Sun, Lishuo Dong, Jiarui Li, Qingwei Li, Xiaolin Tong\",\"doi\":\"10.2147/DMSO.S524000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Type 2 diabetes mellitus (T2DM) has a high prevalence worldwide; its cardiac, renal, and visual complications greatly affect patients' quality of life. This, together with the large patient base, makes clinical health management of T2DM a problem. Existing studies have shown that obesity and the onset of T2DM are highly correlated, which can start from the earliest lipid metabolism problems and ultimately develop into T2DM. Moreover, adipose tissue can also seriously affect patient treatment by affecting insulin secretion, promoting pancreatic β-cell proliferation, and increasing insulin resistance. Our study describes the association between obesity and T2DM, summarizes the role played by the adipose tissue in T2DM, and focuses on fatty acid esters of hydroxy fatty acids (FAHFA), whose role in improving insulin secretion and increasing insulin sensitivity shows greater potential in T2DM. In addition, we summarize the existing more mature clinical treatment strategies, such as life interventions, drugs, and surgery, which can help control blood glucose levels and reduce adipose-related insulin resistance by reducing the adipose tissue. Among these treatments, Chinese medicine is another factor worth exploring. However, due to the influence of geography, culture, and other factors, this method has only achieved some success in China and part of the East Asia region and has been applied clinically. Although there is no evidence of clinical benefit for obesity or adipose tissue, its clinical benefit for T2DM has been demonstrated; therefore, there is still a need to develop it, as well as considerable potential for development.</p>\",\"PeriodicalId\":11116,\"journal\":{\"name\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"volume\":\"18 \",\"pages\":\"2343-2360\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273715/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DMSO.S524000\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S524000","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

2型糖尿病(T2DM)在世界范围内具有很高的患病率;其心脏、肾脏和视觉并发症极大地影响了患者的生活质量。这一点,加上庞大的患者基础,使2型糖尿病的临床健康管理成为一个问题。已有研究表明,肥胖与T2DM的发病高度相关,可以从最早的脂质代谢问题开始,最终发展为T2DM。此外,脂肪组织还会影响胰岛素分泌,促进胰腺β细胞增殖,增加胰岛素抵抗,严重影响患者的治疗。我们的研究描述了肥胖与T2DM之间的关系,总结了脂肪组织在T2DM中的作用,并重点研究了羟基脂肪酸脂肪酸酯(FAHFA),其在改善胰岛素分泌和增加胰岛素敏感性方面的作用在T2DM中显示出更大的潜力。此外,我们总结了现有较为成熟的临床治疗策略,如生命干预、药物、手术等,通过减少脂肪组织来帮助控制血糖水平,降低脂肪相关的胰岛素抵抗。在这些治疗方法中,中医是另一个值得探索的因素。但由于地理、文化等因素的影响,该方法仅在中国和部分东亚地区取得了一定的成功,并在临床上得到了应用。虽然没有证据表明它对肥胖或脂肪组织有临床益处,但它对2型糖尿病的临床益处已得到证实;因此,它仍有发展的需要,也有相当大的发展潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigating the Pathogenesis and Treatment of Type 2 Diabetes from the Perspective of Adipose Tissue.

Type 2 diabetes mellitus (T2DM) has a high prevalence worldwide; its cardiac, renal, and visual complications greatly affect patients' quality of life. This, together with the large patient base, makes clinical health management of T2DM a problem. Existing studies have shown that obesity and the onset of T2DM are highly correlated, which can start from the earliest lipid metabolism problems and ultimately develop into T2DM. Moreover, adipose tissue can also seriously affect patient treatment by affecting insulin secretion, promoting pancreatic β-cell proliferation, and increasing insulin resistance. Our study describes the association between obesity and T2DM, summarizes the role played by the adipose tissue in T2DM, and focuses on fatty acid esters of hydroxy fatty acids (FAHFA), whose role in improving insulin secretion and increasing insulin sensitivity shows greater potential in T2DM. In addition, we summarize the existing more mature clinical treatment strategies, such as life interventions, drugs, and surgery, which can help control blood glucose levels and reduce adipose-related insulin resistance by reducing the adipose tissue. Among these treatments, Chinese medicine is another factor worth exploring. However, due to the influence of geography, culture, and other factors, this method has only achieved some success in China and part of the East Asia region and has been applied clinically. Although there is no evidence of clinical benefit for obesity or adipose tissue, its clinical benefit for T2DM has been demonstrated; therefore, there is still a need to develop it, as well as considerable potential for development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
5.90
自引率
6.10%
发文量
431
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信